Trials / Active Not Recruiting
Active Not RecruitingNCT05867160
Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study
A 12-month, Prospective, Observational Study in Adult Patients With Focal Onset Seizures Who Are Treated With Adjunctive ASM in Real World Setting
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.
Detailed description
The aim of the study is to assess the effectiveness and safety of adjunctive therapy in a real-world setting of patients affected by focal-onset seizures who are eligible to start the treatment with ASM as adjunctive therapy according to the physician's judgment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | ASM as adjunctive therapy | ASM approved as adjunctive therapy |
Timeline
- Start date
- 2023-05-02
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
- First posted
- 2023-05-19
- Last updated
- 2025-09-10
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05867160. Inclusion in this directory is not an endorsement.